Web Search Site Search HCV Patient Assistance Programs (click here for details)   Merck Zepatier Patient Assistance Program (click here for details)   Abbvie - Vikiera Pak Patient Support Program (click here for details)   Sofosbuvir (Sovaldi) - Gilead U.S. Patient Assistance Program (click here for details)   Ryan White Care Act Hepatitis C & B Language (click here for details)   HCV Copayment Assistance - HealthWell Foundation (click here for details)   Current HIV Articles and News Updates     HIV     LATEST UPDATE ON HIV LIPODYSTROPHY: Interview with Dr Grace McComsey   IAS: Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial - (07/24/17)   IAS: Evaluation of lead HIV-1 vaccine regimen in APPROACH: Phase 1/2a study testing heterologous prime boost regimens using mosaic Ad26 and MVA vectors combined with Env protein - (07/24/17)   IAS: Dual regimen with Dolutegravir and Lamivudine maintains virologic suppression even in heavily treatment experienced HIV-infected patients: 96 weeks results from maintenance DOLULAM study - (07/24/17)   IAS: Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily, in Combination With Tenofovir Disoproxil Fumarate/Emtricitabine, in Previously Untreated HIV-1 Infection Through Week 96 - (07/24/17)   IAS: Safety and Efficacy of Long-Acting CAB and RPV as Two Drug IM Maintenance Therapy: LATTE-2 Week 96 Results - (07/24/17)   IAS: ANRS 146 - GeSIDA 7211 OPTIMAL Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-defining event and/or CD4 counts £ 200 cells/ mm3 - (07/24/17)   IAS: Darunavir/Ritonavir Plus 3TC Noninferior to Triple Therapy at 24 Weeks - ANDES Study - A Phase 4, Randomized, Open Label, Study of a Ritonavir-Boosted Darunavir in Fixed Dose Combination (FD-DRV/r) plus Lamivudine Versus FD-DRV/r plus Lamivudine/Tenofovir in Na•ve HIV-1 Infected Subjects - Mark Mascolini - (07/23/17)   IAS: Low Failure Rate With Switch to Integrase Inhibitor STR Despite Archived Mutations - Mark Mascolini - (07/23/17)   IAS: Long-Acting 4/8-Week Cabotegravir/Rilpivirine Maintains Control at 96 Weeks - Mark Mascolini - (07/23/17)   IAS: MK-8591 Protects 8 of 8 Macaques From Rectal SHIV 6 Days After Dosing - Mark Mascolini - (07/23/17)   IAS: CD4 Count at ART Start Rising Across Globe, But Median Still Below 350 / 25% start at below 200 CD4 - Mark Mascolini - (07/23/17)   IAS: Virologic Success Rate 90% at Week 24 With First-Line DTG/3TC in ACTG A5353: ACTG A5353: A pilot study of dolutegravir (DTG) + lamivudine (3TC) for initial treatment of HIV-1-infected participants with HIV-1 RNA <500,000 copies/ml - Mark Mascolini - (07/23/17)   IAS: A Phase 3 Randomized Controlled Clinical Trial of Bictegravir in a Fixed Dose Combination, B/F/TAF, vs DTG/ABC/3TC in Treatment-Naïve Adults at Week 48 - (07/23/17)   IAS: More and earlier cardiovascular events (CVE) and shorter overall survival (OS) in HIV-positive patients (HIV+) compared to the general population differ by sex - (07/23/17)   IAS: Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV - (07/23/17)   IAS: Weekly Oral MK-8591 Protects Male Rhesus Macaques against Repeated Low Dose Intrarectal Challenge with SHIV109CP3 - (07/23/17)   IAS: Ending AIDS: myth or reality? New Infections Increase in Key Populations, UN Update - (07/23/17)   IAS: A global survey of HIV-positive people's attitudes towards cure research - (07/23/17)   Pharm: HIGHER DOLUTEGRAVIR PLASMA TROUGH CONCENTRATION (Ctrough) in PATIENTS presenting SIDE EFFECTS : INTEREST of THERAPEUTIC DRUG MONITORING ? - (07/23/17)   Dual ART Therapy Regimens - (07/23/17)   A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"? - (07/23/17)   Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy - (07/23/17)   Johnson & Johnson at IAS 2017: Latest Innovations from its Janssen Pharmaceutical Companies Include First In-Human Data for Investigational Preventive HIV-1 Vaccine and Phase 3 Pivotal Trial Results for Darunavir-Based, Single-Tablet Regimen - (07/23/17)   More HIV Articles...         News Updates     'Forgotten Ones': Report Examines Challenges For Aging Latinos With HIV - (07/10/17)   FDA Grants Priority Review to HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab - (07/03/17)   LabCorp Completes Acquisition of Assets of Mount Sinai Health System Clinical Outreach Laboratories - (06/28/17)   Walgreens Partners With LabCorp In New Diagnostic Testing Deal - (06/28/17)   More News Updates Articles...     Current Hepatitis C and B Articles     Hepatitis C     EASL: Summary from EASL 2017 for Hepatitis C - Global implementation of Hepatitis C (HCV) treatment: What are the successes, what are the remaining challenges? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (06/01/17)   CROI: Summary from CROI 2017 for viral Hepatitis HCV - elimination on its way: dream or emerging reality? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany   IAS: Glecaprevir/Pibrentasvir Fixed-Dose Combination for 8 or 12 Weeks in Patients Co-Infected With HCV and HIV-1: A Sub-Analysis of the Phase 3 ENDURANCE-1 Study - (07/24/17)   IAS: Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1: The EXPEDITION-2 Study - (07/24/17)   Pharm: MK-3682B Is Not a Clinically Significant CYP3A Inhibitor or Inducer - (07/22/17)   Pharm: No Clinically Significant Interaction of the Proton Pump Inhibitor Omeprazole With the Components of MK-3682B - (07/22/17)   Pharm: Small Increase in Dolutegravir Trough, but Equivalent Total Exposure with Simeprevir - (07/22/17)   Pharm: Dose-selection of odalasvir for use in combination with AL-335 and simeprevir in a phase 2A study using a population pharmacokinetic modelling and simulation approach - (07/22/17)   Pharm: Lack of clinically significant pharmacokinetic interaction between the 3-DAA combination of AL-335, odalasvir and simeprevir for the treatment of chronic HCV infection and an oral contraceptive containing ethinylestradiol and drospirenone - (07/22/17)   U.S. Food and Drug Administration Approves Gilead's Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-Treatment of Adults with Chronic Hepatitis C Virus - (07/22/17)   AASLD: Nivolumab in Patients With Advanced Hepatocellular Carcinoma: the CheckMate 040 Study - (07/22/17)   HCV/IDU-African Americans Bear Greatest Burden-NHANES - (07/18/17)   EASL: A NEW NON-INVASIVE DIAGNOSTIC SCORE TO MONITOR CHANGE IN DISEASE ACTIVITY AND PREDICT FIBROSIS EVOLUTION IN PATIENT WITH NASH - (07/17/17)   EASL: Prospective Prevalence Study of Adult NAFLD/NASH Utilizing Multi-Modality Imaging Compared with Liver Biopsy - (07/17/17)   EASL: Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies - (07/17/17)   EASL: Simple non-invasive fibrosis scores identify patients with NAFLD who progress to advanced fibrosis/cirrhosis: evidence from a large cohort of patients with sequential liver biopsies. - (07/17/17)   New NYS HCV Guidelines - (07/11/17)   EASL: DNA Methylation Signatures in Blood Show Accelerated Epigenetic Aging in Patients with Nonalcoholic Steatohepatitis Compared to Healthy Controls - (07/07/17)   EASL: Changes in Fibrosis, But Not the NAFLD Activity Score, Are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis and Advanced Fibrosis - (07/06/17)   EASL: Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial - (07/05/17)   EASL: INT 747 (obeticholic acid) fails to achieve goals in Japanese study for non-alcoholic steatohepatitis (NASH)- Intercept Pharma + Sumitomo - (07/05/17)   EASL: Starting the battle to control non-alcoholic steatohepatitis [OCA FLINT Study] - Comment - (07/05/17)   EASL: Nonalcoholic Steatohepatitis Drug Pipeline Overview - (07/05/17)   EASL: Regenerate: a phase 3, double-blind, randomized, placebo-controlled multicenter study of obeticholic acid therapy for nonalcoholic steatohepatitis - (07/05/17)   EASL: Elafibranor - (GFT505) NASH Treatment - GOLDEN 505 Study & Commentary - (07/05/17)   More Hep C Articles...         Hepatitis B     DAA / HBV Reactivation - Making Do With What We Have - Editorial - (06/07/17)   Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System - (05/30/17)   More Hep B Articles...   Check Out Our Special NATAP Features   Link to conference listings 2017 Conferences - key HIV & Hepatitis related meetings   not necessarily listed here in order of date being held.   2nd Global HIV Clinical Forum: Integrase Inhibitors - Paris July 22 2017 before IAS   19th Intl Workshop on Co-morbidities and Adverse Drug Reactions in HIV - Milan, October 2017 - October 23-25   EASL - 1st NAFLD Summit Nov 2017 Virology Education Meetings 2017 http://www.virology-education.com/ NASH Biomarkers 5-6 May 2017 Washington D.C., USA INTEREST 16-19 May 2017 Malawi, Africa ACHA 20-21 May 2017 Shenzhen, China APACC 1-3 June 2017 Hong Kong European Meeting on HIV & Hepatitis 7-9 June 2017 Rome, Italy International Workshop on Clinical Pharmacology of Antiviral Therapy 14-16 June 2017 Chicago, USA   Onze masterclasses: Post CROI Symposium 21 maart 2017, Utrecht HIV/HCV Masterclass voor apothekers april 2017 - november 2017, Utrecht HIV Health in Clinical Practice maart - juni 2017, Utrecht   11 February 2017 - 12 February 2017 Renaissance Seattle Hotel, Seattle, WA, USA http://www.virology-education.com/event/upcoming/7th-hiv-women-workshop/ http://www.croiconference.org/ http://www.apasl2017.org/#/ http://www.hivresistance2017.co.za/ http://www.bhiva.org/AnnualConference2017.aspx http://hepatitiscommunitysummit.eu/programme/ https://ilc-congress.eu/ http://www.easl-2017.org/index.html https://hivhepamericas.org/ McCormick Place in Chicago, IL, USA, from 6th to 9th May, 2017 http://ddw2017.org/index.php http://www.viral-hep.org/ 14 - 16 June 2017 in Chicago, IL, USA. http://www.virology-education.com/event/upcoming/18th-international-workshop-clinical-pharmacology-antiviral-therapy/ http://www.ias2017.org/ http://www.asm.org/index.php/asm-microbe-2017 http://www.virology-education.com/event/upcoming/15th-european-meeting-hiv-hepatitis-2017/ http://www.idweekinternational.com/Home.aspx   18 October 2017 in Toronto, Canada http://www.virology-education.com/event/upcoming/international-hbv-cure-workshop-2017/ October 2-3 2017 in New York City http://www.virology-education.com/event/upcoming/8th-hiv-aging-workshop-2017/ https://www.intmedpress.com/comorbidities/ http://www.eacs-conference2017.com/ http://www.aasld.org/events-professional-development/liver-meeting International Viral Hepatitis Elimination Meeting (IVHEM) 2017 17-18 November 2017, Amsterdam, The Netherlands http://www.virology-education.com/event/upcoming/ivhem2017/ Dec 3-8 2017 Big Island, Kona, Hawaii http://www.virology-education.com/event/upcoming/hep-dart-2017/ IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017   18th International Workshop on Clinical Pharmacology of Antiviral Therapy June 14-17, 2017 Chicago, Ill.   The International Liver Congress™ EASL 2017 - European Association for the Study of the Liver Amsterdam, The Netherlands. 2017   26th Conference of the Asian Pacific Association for the Study of the Liver 2017 APASL, Feb 15-19 Shanghai, China   CROI 2017 - Conference on Retroviruses and Opportunistic Infections (CROI) February 13-16, 2017, Seattle WA   AASLD The Liver Meeting Boston MA November 2016   IDWeek 2016, October 26-30, 2016, New Orleans   HIV Glasgow 23-26 October 2016 Glasgow, UK   HIV Research for Prevention (HIVR4P) October 17-19, 2016 Chicago   7th International Workshop on HIV and Aging September 26-27, 2016 Washington, DC   Paris Special EASL Meeting Pais, France September 23-24, 2016   18th International Workshop on Comorbidities and Adverse Drug Reactions in HIV, September 12-13, 2016, New York   International AIDS Conference Durban, South Africa July 18-22, 2016   ASM/ICAAC June 16-20 2016 Boston MA   17th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy June 8-10, 2016, Washington DC   DDW - Digestive Disease Week 2016 San Diego, CA May 16-19, 2016   The International Liver Congress™ EASL - European Association for the Study of the Liver Barcelona, Spain 13-17 April 2016   Conference on Retroviruses and Opportunistic Infections (CROI) February 22-25, 2016, Boston MA   APASL 25th Conference of the Asian Pacific Association for the Study of the Liver Feb 20-24 2016, Tokyo, Japan   HEPDART 2015: Frontiers in Drug Development for Viral Hepatitis December 6-10 2015 Wailea, HI   66th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 13-17 2015   (IWCADRH) 17th Intl Workshop on Comorbidities and Adverse Drug Reactions in HIV Oct 20-22 2015, Barcelona, Spain   15th European AIDS Conference (EACS) October 21-24, 2015 Barcelona   IDSA/IDWeek October 7-11 2015 San Diego   6th International Workshop on HIV and Aging October 5-6, 2015 Washington, DC   ICAAC 2015 55th Interscience Conference on Antimicrobial Agents and Chemotherapy September 5-9, 2015, San Diego, CA   IAS 2015: 8th IAS Conference on HIV Pathogenesis Treatment and Prevention Vancouver Canada 18-22 July 2015   16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy May 26-28, 2015 Washington, DC   DDW - Digestive Disease Week 2015 May 16-19, 2015 Washington DC United States   EASL - The International Liver Congress 2015 50th Annual Meeting of the European Association for the Study of the Liver Vienna, Austria April 22-26   The 24th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2015) Istanbul, Turkey, March 12-15, 2015   22nd Conference on Retroviruses and Opportunistic Infections Seattle Washington Feb 23 - 26, 2015   65th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 7-11 2014   HIV Drug Therapy Glasgow November 2-6, 2014 Glasgow, UK   5th International Workshop on HIV and Aging. October 21-22, 2014 Baltimore   ACG Annual Scientific Meeting Philadelphia, PA, October 20, 2014   16th International Workshop on Co-Morbidities and Adverse Drug Reactions in HIV Philadelphia USA Oct 6-8, 2014   ID Week Oct 8-12 2014 Philadelphia   AASLD/EASL Special Conference on Hepatitis C New York City, New York September 12 - 13   ICAAC 2014 54th Interscience Conference on Antimicrobial Agents and Chemotherapy September 5-9, 2014 Washington, DC   20th International AIDS Conference July 20-25, 2014 Melbourne, Australia   International Workshop on Antiviral Drug Resistance June 3-7 2014, Berlin, Germany   15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy May 19- 21, 2014, Washington, DC   DDW - Digestive Disease Week 2014 May 4, 2014, Chicago Illinois, United States   EASL - The International Liver Congress 2014 49th Annual Meeting of the European Association for the Study of the Liver London, United Kingdom April 9-13   (APASL) 24th Conference of the Asian Pacific Association for the Study of the Liver Brisbane, Australia 12-15 March, 2014   21st Conference on Retroviruses and Opportunistic Infections Boston MA March 3 - 6, 2014   6th HIV Persistence during Therapy - Sixth International Workshop Miami, Dec 3-6, 2013   Fourth International Workshop on HIV and Women January 13-14, 2014 Washington DC   HEPDART 2013: Frontiers in Drug Development for Viral Hepatitis December 8-12, 2013 Big Island, Hawaii   64rd Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC Nov 1-5 2013   4th International Workshop on HIV and Aging October 30-31, 2013 Baltimore, MD   14th European AIDS Conference Oct 16-19 2013 Brussels, Belgium   ID Week October 2-6, 2013 San Francisco   53rd ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy September 10-13 2013, Denver CO   IAS 2013: 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention June 30 - July 3 2013 Kuala Lumpur, Malaysia   View More Conference Reports...   Coming of AGE. A guide to ageing well with HIV - 06/15/11 La informacion Que Necesitas Sobre el VIH - 06/15/10 New Goals and New Drugs for People With Heavy Anti-HIV Drug Experience - 06/05/07 Do you have HIV/HCV Coinfection? - 11/28/06 HIV 101 : The Basics - 11/28/06 VIH 101 : Lo Basico - in Spanish - 11/28/06 HIV 102 : Care and Treatment of HIV - 11/28/06 VIH 102 : Cuidado Y Tratamiento del VIH - in Spanish - 11/28/06 Hepatitis C and Hepatitis C Co-Infection Handbook PDF Version V 11/08/05 Download More NATAP Publications... Support provided by: Support Provided by: Abbvie, Bristol-Myers Squibb, Genentech, Gilead, Janssen Therapeutics, Merck, Roche, & ViiV   Patient Assistance Programs for HCV Therapy from the Drug Manufacturers: Pegylated Interferon and ribavirin If you cannot get reimbursement or coverage for pegylated interferon and ribavirin the manufacturers of pegylated interferon have reimbursement programs which supply free drugs if you qualify. These programs will first help you try to identify sources for reimbursement.   Schering makes Peg-Intron and ribavirin (Rebetol): Call 1-800-521-7157. Roche makes Pegasys and ribavirin (Copegus): 1-800-387-1258.   New Pegasys Patient Assistance Program   has generous provisions for patients who want to start HCV therapy with Pegasys and are uninsured. Since Roche & Genentech merged the Genentech Access Solutions P rogram took over this program starting Sept 1 2010 and as I say it is a generous transparent program.   http://www.pegasysaccesssolutions.com   866 422-2377